Patents Assigned to Morphotek
-
Patent number: 10183975Abstract: Reduced lysine chlorotoxin polypeptides that may be used to generate single species conjugates of chlorotoxin. Conjugates comprising such chlorotoxin polypeptides and pharmaceutical compositions thereof. Methods of using such compositions and/or conjugates.Type: GrantFiled: March 23, 2017Date of Patent: January 22, 2019Assignee: MORPHOTEK, INC.Inventors: Abdellah Sentissi, Douglas B. Jacoby
-
Patent number: 10023632Abstract: Hybridoma lines that secrete human monoclonal antibodies with high binding specificity and biological activity, particularly neutralizing activity against granulocyte-macrophage colony stimulating factor, and methods of generating the hybridoma lines are provided. Target antigens and epitopes are also provided. The antibodies may be used in therapeutic methods, for example in the treatment of cancer, infectious disease, or autoimmune disease.Type: GrantFiled: July 18, 2016Date of Patent: July 17, 2018Assignee: Morphotek, Inc.Inventors: Philip M. Sass, Nicholas C. Nicolaides, Luigi Grasso, Wolfgang Ebel, Jian Li, Qimin Chao, Eric Routhier
-
Patent number: 9915660Abstract: Provided herein are methods for determining the risk that a subject diagnosed with colorectal cancer will develop a recurrence of colorectal cancer and methods of predicting clinical outcome for a subject diagnosed with colorectal cancer by a) determining the level of expression for each marker of a panel of markers in a panel of tumor compartments in a tumor tissue sample from the subject, wherein the panel of markers comprises at least two of TEM1, HIF2?, CAIX, PDGFR?, fibronectin, collagen I, collagen IV, and CD31 and wherein the panel of tumor compartments comprises at least three tumor compartments of pure stroma, tumor, stromal vessel, and tumor vessel; b) determining the TAPPS score for said subject; and c) comparing the TAPPS score of the subject to the TAPPS score of a population of subjects diagnosed with colorectal cancer. Also provided are related computer-implemented methods and systems, kits, and tumor microarrays.Type: GrantFiled: March 15, 2014Date of Patent: March 13, 2018Assignee: Morphotek, Inc.Inventors: Daniel John O'Shannessy, Nicholas C. Nicolaides, Elizabeth B. Somers
-
Patent number: 9868780Abstract: Provided herein are antibodies that specifically bind and neutralize Staphylococcus enterotoxin B. In addition, nucleic acids encoding such antibodies, and cells that express such antibodies are provided. Also provided are methods for treating diseases mediated by, and for neutralizing Staphylococcus enterotoxin B.Type: GrantFiled: May 2, 2016Date of Patent: January 16, 2018Assignee: Morphotek, Inc.Inventors: Philip M. Sass, Nicholas C. Nicolaides, Luigi Grasso, Marc Berger, Tao Sai
-
Patent number: 9771429Abstract: Described herein are antibodies, and antigen-binding fragments thereof, that are specific for tumor endothelial marker 1 (TEM-1), related polynucleotides, expression vectors, and cells that express the described antibodies. Also provided are methods of using the described antibodies, and antigen-binding fragments thereof, and related kits. Provided herein are also methods for diagnosing TEM-1-expressing cancers (such as melanoma, sarcoma, bladder cancer or colon cancer) using the described antibodies, and antigen-binding fragments thereof. The methods involve determining the amount of TEM-1 in a biological sample derived from a subject and comparing this level with the level of TEM-1 in a known standard or reference sample.Type: GrantFiled: August 12, 2015Date of Patent: September 26, 2017Assignee: Morphotek, Inc.Inventor: Daniel John O'Shannessy
-
Patent number: 9650440Abstract: This invention relates to novel monoclonal antibodies that specifically bind to the alpha-folate receptor. In some embodiments, the antibodies inhibit a biological activity of folate receptor-? (FR-?). The antibodies are useful in the treatment of certain cancers, particularly cancers that have increased cell surface expression of the alpha-folate receptor (“FR-?”), such as ovarian, breast, renal, colorectal, lung, endometrial, or brain cancer. The invention also relates to cells expressing the monoclonal antibodies, antibody derivatives, such as chimeric and humanized monoclonal antibodies, antibody fragments, and methods of detecting and treating cancer using the antibodies, derivatives, and fragments.Type: GrantFiled: March 14, 2013Date of Patent: May 16, 2017Assignee: Morphotek, Inc.Inventors: Luigi Grasso, Nicholas C. Nicolaides, Philip M. Sass
-
Patent number: 9637526Abstract: Reduced lysine chlorotoxin polypeptides that may be used to generate single species conjugates of chlorotoxin. Conjugates comprising such chlorotoxin polypeptides and pharmaceutical compositions thereof. Methods of using such compositions and/or conjugates.Type: GrantFiled: December 1, 2015Date of Patent: May 2, 2017Assignee: Morphotek, Inc.Inventors: Abdellah Sentissi, Douglas B. Jacoby
-
Patent number: 9624297Abstract: This invention relates to novel monoclonal antibodies that specifically bind to the alpha-folate receptor. In some embodiments, the antibodies inhibit a biological activity of folate receptor-? (FR-?). The antibodies are useful in the treatment of certain cancers, particularly cancers that have increased cell surface expression of the alpha-folate receptor (“FR-?”), such as ovarian, breast, renal, colorectal, lung, endometrial, or brain cancer. The invention also relates to cells expressing the monoclonal antibodies, antibody derivatives, such as chimeric and humanized monoclonal antibodies, antibody fragments, and methods of detecting and treating cancer using the antibodies, derivatives, and fragments.Type: GrantFiled: July 9, 2009Date of Patent: April 18, 2017Assignee: Morphotek, Inc.Inventors: Luigi Grasso, Nicholas C. Nicolaides, Philip M. Sass
-
Patent number: 9603952Abstract: The present invention is directed to methods and methods for the treatment, inhibition and/or reduction, and detection of metastatic tumors. In some embodiments, the inventive methods include systemic (e.g., intravenous) administration of a chlorotoxin agent that may or may not be labeled. In some embodiments, the inventive methods allow treatment, inhibition and/or reduction, and detection of metastases in the brain. In some embodiments, neovascularization is inhibited and/or newly formed vessels are caused to regress.Type: GrantFiled: May 4, 2015Date of Patent: March 28, 2017Assignee: MORPHOTEK, INC.Inventors: Alison O'Neill, Douglas B. Jacoby, Abdellah Sentissi, Kamala Kesavan, E. Michael Egan
-
Patent number: 9522195Abstract: This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and have the ability in the alternative to become internalized by cells expressing folate receptor alpha (FRA) and to induce an immune effector activity such as antibody-dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic agents to FRA-expressing cells as well as in eliciting an immune-effector activity particularly on tumor cells and precursors. The invention is also related to nucleotides encoding the antibodies of the invention, cells expressing the antibodies; methods of detecting cancer cells; and methods of treating cancer using the antibodies.Type: GrantFiled: July 27, 2015Date of Patent: December 20, 2016Assignee: Morphotek, Inc.Inventors: Luigi Grasso, Nicholas C. Nicolaides, Philip M. Sass
-
Patent number: 9512223Abstract: The application provides methods of detection, diagnosis, prognosis, prophylaxis and treatment of folate receptor-alpha-expressing gastric cancer using antibodies that specifically bind to folate receptor alpha.Type: GrantFiled: March 14, 2013Date of Patent: December 6, 2016Assignee: Morphotek, Inc.Inventor: Yasutsuna Sasaki
-
Patent number: 9505842Abstract: The invention provides methods for inhibiting the interaction of endosialin with endosialin ligands. The inhibition is effectuated on the genetic level, by inhibiting endosialin gene expression, and on the protein level, by blocking the interaction of cell-surface expressed endosialin with ligands such as fibronectin and collagen. The invention provides methods for identifying inhibitors of the interaction of endosialin with endosialin ligands. Also provided are methods for inhibiting angiogenesis and neovascularization in vivo and in vitro.Type: GrantFiled: October 8, 2014Date of Patent: November 29, 2016Assignee: Morphotek, Inc.Inventors: Yuhong Zhou, Brian Tomkowicz, Luigi Grasso, Nicholas C. Nicolaides, Philip M. Sass
-
Patent number: 9422367Abstract: Hybridoma lines that secrete human monoclonal antibodies with high binding specificity and biological activity, particularly neutralizing activity against granulocyte-macrophage colony stimulating factor, and methods of generating the hybridoma lines are provided. Target antigens and epitopes are also provided. The antibodies may be used in therapeutic methods, for example in the treatment of cancer, infectious disease, or autoimmune disease.Type: GrantFiled: November 26, 2013Date of Patent: August 23, 2016Assignee: Morphotek, Inc.Inventors: Philip M. Sass, Nicholas C. Nicolaides, Luigi Grasso, Jian Li, Qimin Chao, Eric Routhier, Wolfgang Ebel
-
Patent number: 9359428Abstract: Provided herein are antibodies that specifically bind and neutralize Staphylococcus enterotoxin B. In addition, nucleic acids encoding such antibodies, and cells that express such antibodies are provided. Also provided are methods for treating diseases mediated by, and for neutralizing Staphylococcus enterotoxin B.Type: GrantFiled: October 15, 2014Date of Patent: June 7, 2016Assignee: Morphotek, Inc.Inventors: Philip M. Sass, Nicholas C. Nicolaides, Luigi Grasso, Marc Berger, Tao Sai
-
Patent number: 9234015Abstract: Reduced lysine chlorotoxin polypeptides that may be used to generate single species conjugates of chlorotoxin. Conjugates comprising such chlorotoxin polypeptides and pharmaceutical compositions thereof. Methods of using such compositions and/or conjugates.Type: GrantFiled: August 1, 2014Date of Patent: January 12, 2016Assignee: Morphotek, Inc.Inventors: Abdellah Sentissi, Douglas B. Jacoby
-
Patent number: 9144614Abstract: This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and have the ability in the alternative to become internalized by cells expressing folate receptor alpha (FRA) and to induce an immune effector activity such as antibody-dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic agents to FRA-expressing cells as well as in eliciting an immune-effector activity particularly on tumor cells and precursors. The invention is also related to nucleotides encoding the antibodies of the invention, cells expressing the antibodies; methods of detecting cancer cells; and methods of treating cancer using the antibodies.Type: GrantFiled: January 24, 2012Date of Patent: September 29, 2015Assignee: Morphotek, Inc.Inventors: Nicholas C. Nicolaides, Luigi Grasso, Philip M. Sass
-
Patent number: 9139656Abstract: Described herein are antibodies, and antigen-binding fragments thereof, that are specific for tumor endothelial marker 1 (TEM-1), related polynucleotides, expression vectors, and cells that express the described antibodies. Also provided are methods of using the described antibodies, and antigen-binding fragments thereof, and related kits. Provided herein are also methods for diagnosing TEM-1-expressing cancers (such as melanoma, sarcoma, bladder cancer, gastric cancer, hepatocellular cancer, or colon cancer) using the described antibodies, and antigen-binding fragments thereof. The methods involve determining the amount of TEM-1 in a biological sample derived from a subject and comparing this level with the level of TEM-1 in a known standard or reference sample.Type: GrantFiled: March 14, 2013Date of Patent: September 22, 2015Assignee: Morphotek, Inc.Inventor: Daniel John O'Shannessy
-
Patent number: 9115197Abstract: This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and become internalized by mesothelin-positive cells and also induce an immune effector activity such as antibody dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic agents to mesothelin expressing cells as well as eliciting an immune-effector activity particularly on tumor cells and precursors. The invention is also related to cells expressing the monoclonal antibodies, polyclonal antibodies, antibody derivatives, such as human, humanized, and chimeric monoclonal antibodies, antibody fragments, mammalian cells expressing the monoclonal antibodies, derivatives and fragments, and methods of treating cancer using the antibodies, derivatives and fragments.Type: GrantFiled: January 6, 2014Date of Patent: August 25, 2015Assignee: Morphotek, Inc.Inventors: Wolfgang Ebel, Luigi Grasso, Nicholas C. Nicolaides, Philip M. Sass, Eric Routhier
-
Patent number: 9023595Abstract: The present invention is directed to methods and methods for the treatment, inhibition and/or reduction, and detection of metastatic tumors. In some embodiments, the inventive methods include systemic (e.g., intravenous) administration of a chlorotoxin agent that may or may not be labeled. In some embodiments, the inventive methods allow treatment, inhibition and/or reduction, and detection of metastases in the brain. In some embodiments, neovascularization is inhibited and/or newly formed vessels are caused to regress.Type: GrantFiled: May 23, 2012Date of Patent: May 5, 2015Assignee: Morphotek, Inc.Inventors: Alison O'Neill, Douglas B. Jacoby, Abdellah Sentissi, Kamala Kesavan, Laura Sen
-
Patent number: 9018347Abstract: Reduced lysine chlorotoxin polypeptides that may be used to generate single species conjugates of chlorotoxin. Conjugates comprising such chlorotoxin polypeptides and pharmaceutical compositions thereof. Methods of using such compositions and/or conjugates.Type: GrantFiled: February 4, 2011Date of Patent: April 28, 2015Assignee: Morphotek, Inc.Inventors: Abdellah Sentissi, Douglas B. Jacoby